Bristol UFT Review Standards Questioned By Rep. Bliley In Letter To FDA
Executive Summary
Bristol-Myers Squibb's oral colorectal cancer therapy UFT should be available as a "gentler" alternative to regimens containing Pharmacia's Camptosar, House Commerce Committee Chairman Bliley (R-Va.) told FDA in an April 17 letter to Commissioner Henney.